Navigation Links
Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
Date:4/15/2009

New Business Spin-off to Focus on Drug Development for Neurological Conditions

BROOMFIELD, Colo., April 15 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today the formation of Neuera Pharmaceuticals, Inc., a drug development company. The new company will focus on the discovery and development of proprietary small molecule drugs for acute and chronic neurological conditions where the mechanism of defective energy metabolism or hypometabolism is involved.

Neuera Pharmaceuticals will operate as a wholly owned subsidiary and will be spun out of Accera as a stand-alone company after the completion of a $12 million series A financing round. Existing Accera investors have already committed to participate in the capital raise. Some of Accera's management and staff will join the newly formed company, and the current small molecule pipeline at Accera including the preclinical compounds, AC-0523 and AC-8632, have been transferred to Neuera. In addition to in-house development of small molecules, Neuera Pharmaceuticals is actively pursuing the license or acquisition of late clinical-stage products for CNS diseases or conditions that complement the hypometabolism platform.

"The division of our pipeline and Axona(TM) product between two organizations allows each one to concentrate on the unique regulatory requirements for their respective class of products. Each company will be a regulatory and market pure play that is better appreciated by investors and the industry," said Steve Orndorff, Ph.D., Accera's founder and CEO. "Furthermore, we believe the success of Axona in the marketplace will provide a real world validation of the energy metabolism platform for Neuera Pharmaceuticals' pipeline development."

On March 2nd Accera launched Axona, a first-in-class medical food product for the clinical dietary managem
'/>"/>

SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Accera, Inc. to Present at Upcoming Investor Conferences
2. Dr. Thomas Werner Elected to Accera, Inc.s Board of Directors
3. Accera, Inc. Sponsors Alzheimers Associations 2009 ICAD Conference
4. Accera, Inc. Completes $35 Million Series C Financing
5. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
6. Accera, Inc. to Present at the 4th Annual BIO Investor Forum
7. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
8. US Oncology Launches New Web Site
9. Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence
10. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
11. Selexis Launches Biosimilar Cell Line Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014 Cloud Pharmaceuticals, ... design and development, announced today the expansion of ... has been granted supercomputing time at Argonne National ... Through a discretionary allocation of ... Facility (ALCF), researchers at Cloud Pharmaceuticals will use ...
(Date:7/14/2014)... 2014 Throughout this past June ... clinical trials space, representing 38 countries globally, registered ... “Optimizing Patient Participation in Clinical Trials. Attract. Engage. ... internationally renowned R&D expert, Ken Getz, of Tufts ... Drug Development through Patient Centricity. , Throughout this ...
(Date:7/14/2014)... , July 14, 2014 Minerva Neurosciences (NASDAQ: ... of new therapies to treat neuropsychiatric diseases and disorders, ... been appointed vice president of finance and chief accounting ... is a senior executive with more than 20 years ... and life science companies. His background includes the management ...
(Date:7/14/2014)... 14, 2014 PatientCrossroads, pioneer ... announced that three PatientCrossroads-based patient registries—DuchenneConnect, for ... Syndrome International Registry; and the NephCure Kidney ... contracts by the Patient-Centered Outcomes Research Institute ... a new health data network called PCORnet: ...
Breaking Biology Technology:Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3
... , Most Basic Recommended Cecil Instrumentation: , ... 500 l loop , Fraction collector , Column ... : , Researchers need to understand ... protein expression in healthy and diseased cells. , Hence the ...
... reliable and accurate long-range PCR and RT-PCR , ... RT-PCR Kits provide dedicated and highly reliable solutions for long-range,amplification from genomic DNA and cDNA. ... , QIAGEN LongRange PCR ... Amplification of extremely long PCR products up to 40 kb DNA or,12.5 kb ...
... LOS ANGELES, CA (August 10, 2006) - DoveBid, Inc., ( http://www.dovebid.com ... auction and valuation services, announced , today it ... Exchange auction online, on August 15, 2006. The event marks a milestone ... practice, and is expected , to bring to-date ...
Cached Biology Technology:Semi Preparative Purification of Proteins 2QIAGEN LongRange PCR and 2Step RT-PCR Kits 2World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition 2World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition 3
(Date:7/14/2014)... 2014 How does oxygen control insect body size? What ... in the first issue of Current Opinion in Insect ... and more questions. , Current Opinion in Insect Science ... series. It is a review journal that aims to provide ... expanding volume of information published in the field of insect ...
(Date:7/14/2014)... The Biogerontology Research Foundation (BGRF), a UK-based charity ... challenges of a rapidly ageing population, hosted the ... 30th, with Aging Analytics, a company supporting financial ... , The speakers at the forum included: , ... Kong on ,Impact Investment to Advance Longevity Research, ...
(Date:7/14/2014)... discovery and description of Rhipidocyrtus muiri - a ... to represent a new genus and species. The long and ... is discussed in a recent paper published in the open ... male, and only known specimen of Rhipidocyrtus muiri , ... this it was transferred among several researchers in the early ...
Breaking Biology News(10 mins):BGRF hosts inaugural 21st Century Medicine Forum 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 3
... the National Institutes of Health will explore the role ... by NIH,s National Institute of Environmental Health Sciences (NIEHS), ... people more vulnerable to heat exposure; changing weather patterns; ... toxic chemicals; and the negative effects of climate change ...
... discovered in the 16-23 million years old sediments of the ... Helophorus sibiricus , a member of the water scavenger ... in Eurasia and reaches even North America. The species was ... based on specimens collected at Lake Baikal. It is aquatic ...
... 2011. In the central Arctic the proportion of old, thick ... largely consists of thin, one-year-old floes. This is one of ... Polar and Marine Research in the Helmholtz Association brought back ... The ship arrived at its home port of Bremerhaven ...
Cached Biology News:NIH launches research program to explore health effects from climate change 2NIH launches research program to explore health effects from climate change 3A living species of aquatic beetle found in 20-million-year-old sediments 2Young and thin instead of old and bulky 2Young and thin instead of old and bulky 3Young and thin instead of old and bulky 4
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
...
Luminometers...
Biology Products: